These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

272 related articles for article (PubMed ID: 31488153)

  • 21. Circulating Nucleic Acids Are Associated With Outcomes of Patients With Pancreatic Cancer.
    Bernard V; Kim DU; San Lucas FA; Castillo J; Allenson K; Mulu FC; Stephens BM; Huang J; Semaan A; Guerrero PA; Kamyabi N; Zhao J; Hurd MW; Koay EJ; Taniguchi CM; Herman JM; Javle M; Wolff R; Katz M; Varadhachary G; Maitra A; Alvarez HA
    Gastroenterology; 2019 Jan; 156(1):108-118.e4. PubMed ID: 30240661
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Early Circulating Tumour DNA Variations Predict Tumour Response in Melanoma Patients Treated with Immunotherapy.
    Keller L; Guibert N; Casanova A; Brayer S; Farella M; Delaunay M; Gilhodes J; Martin E; Balagué G; Favre G; Pradines A; Meyer N
    Acta Derm Venereol; 2019 Feb; 99(2):206-210. PubMed ID: 30393817
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Use of circulating tumoral DNA to guide treatment for metastatic melanoma.
    Herbreteau G; Charpentier S; Vallée A; Denis MG
    Pharmacogenomics; 2019 Dec; 20(18):1259-1270. PubMed ID: 31596166
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Longitudinal Relationship between Idylla Plasma ctBRAF V600 Mutation Detection and Tumor Burden in Patients with Metastatic Melanoma.
    Linder MW; Egger ME; Van Meter T; Rai SN; Valdes R; Hall MB; Wu X; Alghamdi N; Chesney JA
    Mol Diagn Ther; 2021 May; 25(3):361-371. PubMed ID: 33970440
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Immune-related adverse events correlate with improved survival in patients undergoing anti-PD1 immunotherapy for metastatic melanoma.
    Indini A; Di Guardo L; Cimminiello C; Prisciandaro M; Randon G; De Braud F; Del Vecchio M
    J Cancer Res Clin Oncol; 2019 Feb; 145(2):511-521. PubMed ID: 30539281
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Prognostic and theranostic 18F-FDG PET biomarkers for anti-PD1 immunotherapy in metastatic melanoma: association with outcome and transcriptomics.
    Seban RD; Nemer JS; Marabelle A; Yeh R; Deutsch E; Ammari S; Moya-Plana A; Mokrane FZ; Gartrell RD; Finkel G; Barker L; Bigorgne AE; Schwartz LH; Saenger Y; Robert C; Dercle L
    Eur J Nucl Med Mol Imaging; 2019 Oct; 46(11):2298-2310. PubMed ID: 31346755
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Prospective assessment of circulating tumor DNA in patients with metastatic uveal melanoma treated with tebentafusp.
    Rodrigues M; Ramtohul T; Rampanou A; Sandoval JL; Houy A; Servois V; Mailly-Giacchetti L; Pierron G; Vincent-Salomon A; Cassoux N; Mariani P; Dutriaux C; Pracht M; Ryckewaert T; Kurtz JE; Roman-Roman S; Piperno-Neumann S; Bidard FC; Stern MH; Renault S
    Nat Commun; 2024 Oct; 15(1):8851. PubMed ID: 39402032
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Detection of clinical progression through plasma ctDNA in metastatic melanoma patients: a comparison to radiological progression.
    Marsavela G; McEvoy AC; Pereira MR; Reid AL; Al-Ogaili Z; Warburton L; Khattak MA; Abed A; Meniawy TM; Millward M; Ziman MR; Calapre L; Gray ES
    Br J Cancer; 2022 Feb; 126(3):401-408. PubMed ID: 34373567
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Targeted sequencing of plasma cell-free DNA to predict response to PD1 inhibitors in advanced non-small cell lung cancer.
    Guibert N; Jones G; Beeler JF; Plagnol V; Morris C; Mourlanette J; Delaunay M; Keller L; Rouquette I; Favre G; Pradines A; Mazieres J
    Lung Cancer; 2019 Nov; 137():1-6. PubMed ID: 31518912
    [TBL] [Abstract][Full Text] [Related]  

  • 30. RAS/BRAF Circulating Tumor DNA Mutations as a Predictor of Response to First-Line Chemotherapy in Metastatic Colorectal Cancer Patients.
    Yao J; Zang W; Ge Y; Weygant N; Yu P; Li L; Rao G; Jiang Z; Yan R; He L; Yu Y; Jin M; Cheng G; An G
    Can J Gastroenterol Hepatol; 2018; 2018():4248971. PubMed ID: 29707525
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Circulating tumor DNA (ctDNA) detection is associated with shorter progression-free survival in advanced melanoma patients.
    Marczynski GT; Laus AC; Dos Reis MB; Reis RM; Vazquez VL
    Sci Rep; 2020 Oct; 10(1):18682. PubMed ID: 33122747
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Modeled Prognostic Subgroups for Survival and Treatment Outcomes in BRAF V600-Mutated Metastatic Melanoma: Pooled Analysis of 4 Randomized Clinical Trials.
    Hauschild A; Larkin J; Ribas A; Dréno B; Flaherty KT; Ascierto PA; Lewis KD; McKenna E; Zhu Q; Mun Y; McArthur GA
    JAMA Oncol; 2018 Oct; 4(10):1382-1388. PubMed ID: 30073321
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Assessing tumor heterogeneity using ctDNA to predict and monitor therapeutic response in metastatic breast cancer.
    Ma F; Guan Y; Yi Z; Chang L; Li Q; Chen S; Zhu W; Guan X; Li C; Qian H; Xia X; Yang L; Zhang J; Husain H; Liao Z; Futreal A; Huang J; Yi X; Xu B
    Int J Cancer; 2020 Mar; 146(5):1359-1368. PubMed ID: 31241775
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Pre-operative ctDNA predicts survival in high-risk stage III cutaneous melanoma patients.
    Lee JH; Saw RP; Thompson JF; Lo S; Spillane AJ; Shannon KF; Stretch JR; Howle J; Menzies AM; Carlino MS; Kefford RF; Long GV; Scolyer RA; Rizos H
    Ann Oncol; 2019 May; 30(5):815-822. PubMed ID: 30860590
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Microarray-based analysis of the BRAF V600 mutations in circulating tumor DNA in melanoma patients.
    Emelyanova MA; Telysheva EN; Orlova KV; Ryabaya OO; Snigiryova GP; Abramov IS; Mikhailovich VM
    Cancer Genet; 2021 Jan; 250-251():25-35. PubMed ID: 33249369
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Prognostic Value of ctDNA Mutation in Melanoma: A Meta-Analysis.
    Zheng Y; Sun H; Cong L; Liu C; Sun Q; Wu N; Cong X
    J Oncol; 2021; 2021():6660571. PubMed ID: 34035810
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Personalized follow-up of circulating DNA in resected stage III/IV melanoma: PERCIMEL multicentric prospective study protocol.
    Geoffrois L; Harlé A; Sahki N; Sikanja A; Granel-Brocard F; Hervieu A; Mortier L; Jeudy G; Michel C; Nardin C; Huin-Schohn C; Merlin JL
    BMC Cancer; 2023 Jun; 23(1):554. PubMed ID: 37328818
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Circulating tumour DNA dynamics predict recurrence in stage III melanoma patients receiving neoadjuvant immunotherapy.
    Chan WY; Lee JH; Stewart A; Diefenbach RJ; Gonzalez M; Menzies AM; Blank C; Scolyer RA; Long GV; Rizos H
    J Exp Clin Cancer Res; 2024 Aug; 43(1):238. PubMed ID: 39169411
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Circulating Tumor DNA Measurement by Picoliter Droplet-Based Digital PCR and Vemurafenib Plasma Concentrations in Patients with Advanced BRAF-Mutated Melanoma.
    Garlan F; Blanchet B; Kramkimel N; Puszkiel A; Golmard JL; Noe G; Dupin N; Laurent-Puig P; Vidal M; Taly V; Thomas-Schoemann A
    Target Oncol; 2017 Jun; 12(3):365-371. PubMed ID: 28527094
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Treatment Sequencing and Clinical Outcomes in BRAF-Positive and BRAF-Negative Unresectable and Metastatic Melanoma Patients Treated with New Systemic Therapies in Routine Practice.
    Czarnecka AM; Teterycz P; Mariuk-Jarema A; Lugowska I; Rogala P; Dudzisz-Sledz M; Switaj T; Rutkowski P
    Target Oncol; 2019 Dec; 14(6):729-742. PubMed ID: 31754963
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 14.